[ad_1]
Chinese Vice Premier Han Zheng said in Macau on Tuesday that when the country develops a vaccine against COVID-19, it will be a “global public good.”
Once China has the vaccine, “it will be available as a global public good,” Han Zheng assured at the opening of the International Science, Technology and Innovation Forum (ISTIF) Conference, held in Macau and organized by the Boao Forum. , known as “Asian Davos”.
The Chinese official also stressed that when there is a Chinese vaccine, this “means the defeat of covid-19.”
Also in his speech, the Chinese vice premier assured that Beijing wants to work with all the countries of the world to control the pandemic, arguing that “together” it will be possible to develop a treatment and a vaccine.
These statements in Macau come one day after the Brazilian health authority have announced that suspended clinical trials of the Coronavac vaccine, Chinese laboratory Sinovac, against the new coronavirus, after a “serious” incident with a volunteer.
Coronavac is also being tested in China, Turkey, Bangladesh and Indonesia.
In a statement, the National Health Surveillance Agency (Anvisa) reported that it decided to stop the clinical trial of the Coronavac vaccine “after the occurrence of a serious adverse event” on October 29.
Anvisa did not provide further information on the incident, referring only to the fact that the category of “adverse event” may include death, potentially fatal side effects, persistent or significant disability or disability, hospitalization or other “clinically significant event.”
“With the discontinuation of the study, new volunteers will not be able to be vaccinated,” the agency said, adding that it will “evaluate the data observed so far and judge the risk / benefit of continuing” the tests.
The suspension of Coronavac’s clinical trials, involving 9,000 volunteers, came a day after US pharmaceutical giant Pfizer announced that its COVID-19 vaccine was 90% effective in tests.
The candidate vaccines from Pfizer and Sinovac are in phase 3 trials, the last phase before receiving regulatory approval.
[ad_2]
